# Snapshot Pipeline Intelligence — Johnson & Johnson

## Run coverage & provenance
- Run date (UTC): 2026-01-08
- Pipeline source URL: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q3/JNJ-Pipeline-3Q25.pdf
- Stored pipeline PDF: `sources/jnj/2026-01-08.pdf`
- Pipeline SHA256: `7be7a71814f547e8772f826b14552f40244c9d6a9dd0548d8b79a85c3f1a9e04`
- Programs extracted: 101
- Note: source PDF unchanged; reused prior extracted snapshot to avoid OCR/LLM variability.
- Inventory export (CSV): `reports/jnj/2026-01-08.programs.csv`
- Evidence pack (JSON): `reports/jnj/2026-01-08.evidence.json`

## Pipeline size by phase (snapshot)
- Unknown: 101

## Programs inventory (excerpt)
_Full inventory is in the CSV export: `reports/jnj/2026-01-08.programs.csv`._

| Asset | Indication | Phase | Page |
|---|---|---:|---:|
| AKEEGA (niraparib/abiraterone) | M1 Metastatic Castration-Sensitive Prostate Cancer |  |  |
| Bleximenib | Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine |  |  |
| Bleximenib | Relapsed Refractory Acute Myeloid Leukemia |  |  |
| CABENUVA | HIV Adolescents |  |  |
| CAPLYTA (lumateperone) | Adjunctive Treatment for Major Depressive Disorder |  |  |
| CAPLYTA (lumateperone) | Bipolar Mania |  |  |
| CAPLYTA (lumateperone) | Pediatric Psychiatric Indications |  |  |
| CARVYKTI (Ciltacabtagene autoleucel) | Frontline Multiple Myeloma TNI |  |  |
| CARVYKTI (Ciltacabtagene autoleucel) | Frontline Multiple Myeloma Transplant Eligible vs ASCT |  |  |
| DARZALEX (daratumumab) | Frontline multiple myeloma transplant ineligible |  |  |
| DARZALEX (daratumumab) | Smoldering Multiple Myeloma |  |  |
| ERLEADA (apalutamide) | High Risk Prostate Cancer |  |  |
| ERLEADA (apalutamide) | Localized Prostate Cancer |  |  |
| icotrokinra | Psoriasis |  |  |
| icotrokinra | Psoriatic Arthritis |  |  |
| icotrokinra | Ulcerative Colitis |  |  |
| IMAAVY (nipocalimab) | Generalized Myasthenia Gravis |  |  |
| IMAAVY (nipocalimab) | Generalized Myasthenia Gravis Pediatrics |  |  |
| IMBRUVICA (ibrutinib) | Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) |  |  |
| IMBRUVICA (ibrutinib) | Frontline Mantle Cell Lymphoma |  |  |
| INLEXZO (gemcitabine intravesical system) | High Risk Non Muscle Invasive Bladder Cancer BGC Experienced |  |  |
| INLEXZO (gemcitabine intravesical system) | Non Muscle Invasive Bladder Cancer |  |  |
| INLEXZO (gemcitabine intravesical system) | Non Muscle Invasive Bladder Cancer BCG-naïve High Risk |  |  |
| ITI-1284 | Alzheimer's Disease-Related Agitation |  |  |
| ITI-1284 | Alzheimer's Disease-Related Psychosis |  |  |
| ITI-1284 | Generalized Anxiety Disorder |  |  |
| JNJ-0387 | Solid Tumors |  |  |
| JNJ-0631 (ARX305) | Renal Cancer |  |  |
| JNJ-0683 (ARX788) | Breast Cancer |  |  |
| JNJ-1493 | Hematological Malignancies |  |  |

## ClinicalTrials.gov coverage
- API base: https://clinicaltrials.gov/api/v2
- Programs with matches: 32/101
- Phase mismatches: 0
- Stored CT.gov evidence: `sources/jnj/ctgov/2026-01-08`

## SEC EDGAR coverage
- Filings since: 2025-10-10
- New filings processed: 0
- Filings with extracted events: 0
- Stored EDGAR evidence: `sources/jnj/sec/2026-01-08`

## Press coverage
- Feed URL: https://www.jnj.com/rss-feed/all
- Links scanned: 10
- New releases processed: 0
- Releases with extracted events: None
- Stored press evidence: `sources/jnj/press/2026-01-08`

### Latest press releases (coverage)
- 2026-01-08 — already processed — Johnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-celebrates-innovation-in-cancer-research-with-2025-dr-paul-janssen-award
- 2026-01-07 — already processed — Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration
- 2026-01-06 — already processed — Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-application-to-the-european-medicines-agency-for-tecvayli-teclistamab-in-combination-with-darzalex-daratumumab-subcutaneous-formulation-for-patients-with-relapsed-refractory-multiple-myeloma
- 2026-01-06 — already processed — Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-unveils-new-data-showing-nipocalimab-is-the-first-and-only-investigational-fcrn-blocker-with-potential-to-reduce-systemic-lupus-erythematosus-sle-activity-in-a-phase-2-study
- 2026-01-02 — already processed — Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-quarterly-dividend-for-first-quarter-2026
- 2025-12-29 — already processed — Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-halda-therapeutics-and-its-novel-platform-to-revolutionize-cancer-treatment-and-enable-next-generation-oral-therapies
- 2025-12-26 — already processed — Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-the-phase-2b-duplex-ad-study
- 2025-12-22 — already processed — European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
  - https://www.jnj.com/media-center/press-releases/european-commission-approves-tremfya-guselkumab-for-the-treatment-of-children-with-plaque-psoriasis-marking-the-first-paediatric-indication-for-an-il-23-inhibitor
- 2025-12-19 — already processed — Johnson & Johnson Backs HRS Registry to Advance Real-World Evidence in PFA
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-backs-hrs-registry-to-advance-real-world-evidence-in-pfa
- 2025-12-18 — already processed — Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
  - https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-fda-approval-for-trufill-n-bca-liquid-embolic-system-for-the-treatment-of-symptomatic-chronic-subdural-hematoma

## Pipeline inventory (full list)
| Asset | Indication | Phase | Page |
|---|---|---|---:|
| AKEEGA (niraparib/abiraterone) | M1 Metastatic Castration-Sensitive Prostate Cancer |  |  |
| Bleximenib | Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine |  |  |
| Bleximenib | Relapsed Refractory Acute Myeloid Leukemia |  |  |
| CABENUVA | HIV Adolescents |  |  |
| CAPLYTA (lumateperone) | Adjunctive Treatment for Major Depressive Disorder |  |  |
| CAPLYTA (lumateperone) | Bipolar Mania |  |  |
| CAPLYTA (lumateperone) | Pediatric Psychiatric Indications |  |  |
| CARVYKTI (Ciltacabtagene autoleucel) | Frontline Multiple Myeloma TNI |  |  |
| CARVYKTI (Ciltacabtagene autoleucel) | Frontline Multiple Myeloma Transplant Eligible vs ASCT |  |  |
| DARZALEX (daratumumab) | Frontline multiple myeloma transplant ineligible |  |  |
| DARZALEX (daratumumab) | Smoldering Multiple Myeloma |  |  |
| ERLEADA (apalutamide) | High Risk Prostate Cancer |  |  |
| ERLEADA (apalutamide) | Localized Prostate Cancer |  |  |
| icotrokinra | Psoriasis |  |  |
| icotrokinra | Psoriatic Arthritis |  |  |
| icotrokinra | Ulcerative Colitis |  |  |
| IMAAVY (nipocalimab) | Generalized Myasthenia Gravis |  |  |
| IMAAVY (nipocalimab) | Generalized Myasthenia Gravis Pediatrics |  |  |
| IMBRUVICA (ibrutinib) | Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) |  |  |
| IMBRUVICA (ibrutinib) | Frontline Mantle Cell Lymphoma |  |  |
| INLEXZO (gemcitabine intravesical system) | High Risk Non Muscle Invasive Bladder Cancer BGC Experienced |  |  |
| INLEXZO (gemcitabine intravesical system) | Non Muscle Invasive Bladder Cancer |  |  |
| INLEXZO (gemcitabine intravesical system) | Non Muscle Invasive Bladder Cancer BCG-naïve High Risk |  |  |
| ITI-1284 | Alzheimer's Disease-Related Agitation |  |  |
| ITI-1284 | Alzheimer's Disease-Related Psychosis |  |  |
| ITI-1284 | Generalized Anxiety Disorder |  |  |
| JNJ-0387 | Solid Tumors |  |  |
| JNJ-0631 (ARX305) | Renal Cancer |  |  |
| JNJ-0683 (ARX788) | Breast Cancer |  |  |
| JNJ-1493 | Hematological Malignancies |  |  |
| JNJ-1887 sCD59 | Geographic Atrophy |  |  |
| JNJ-1900 (NBTXR3) | Head and Neck Cancer |  |  |
| JNJ-1900 (NBTXR3) | Lung Cancer |  |  |
| JNJ-2056 (tau active immunotherapy) | Alzheimer's Disease |  |  |
| JNJ-2638 | Gastrointestinal Cancer |  |  |
| JNJ-2761 | Multiple Myeloma |  |  |
| JNJ-3413 | Lymphoma |  |  |
| JNJ-4496 | Hematological Malignancies |  |  |
| JNJ-4680 | Lung Cancer |  |  |
| JNJ-4681 | Hematological Malignancies |  |  |
| JNJ-4804 Co-antibody Therapy | Crohn's Disease |  |  |
| JNJ-4804 Co-antibody Therapy | Psoriatic Arthritis |  |  |
| JNJ-4804 Co-antibody Therapy | Ulcerative Colitis |  |  |
| JNJ-4916 | Lung Cancer |  |  |
| JNJ-5108 | Immunological Diseases |  |  |
| JNJ-5120 | Major Depressive Disorder |  |  |
| JNJ-5322 | Multiple Myeloma |  |  |
| JNJ-5939 | Atopic Dermatitis |  |  |
| JNJ-6420 | Prostate Cancer |  |  |
| JNJ-6848 | Immunological Diseases |  |  |
| JNJ-7446 | Lung Cancer |  |  |
| JNJ-7528 | Atopic Dermatitis |  |  |
| JNJ-8177 (ARX517) | Prostate Cancer |  |  |
| JNJ-8377 | Lymphoma |  |  |
| JNJ-8543 | Hematological Malignancies |  |  |
| JNJ-9401 | Prostate Cancer |  |  |
| JNJ-9530 | Hematological Malignancies |  |  |
| JNJ-9892 | Hematological Malignancies |  |  |
| JNJ-9968 | Hematological Malignancies |  |  |
| macitentan | Pulmonary Arterial Hypertension 75mg |  |  |
| milvexian (Factor Xla) | Acute Coronary Syndrome |  |  |
| milvexian (Factor Xla) | Atrial Fibrillation |  |  |
| milvexian (Factor Xla) | Secondary Stroke Prevention |  |  |
| nipocalimab | Chronic Inflammatory Demyelinating Polyneuropathy |  |  |
| nipocalimab | Fetal and Neonatal Alloimmune Thrombocytopenia |  |  |
| nipocalimab | Hemolytic Disease of the Fetus and Newborn |  |  |
| nipocalimab | Idiopathic Inflammatory Myopathy |  |  |
| nipocalimab | Sjogren's Disease |  |  |
| nipocalimab | Systemic Lupus Erythematosus |  |  |
| nipocalimab | Warm Autoimmune Hemolytic Anemia |  |  |
| pasritamig | Prostate Cancer |  |  |
| posdinemab | Alzheimer's Disease |  |  |
| RPGR Gene Therapy | Retinitis Pigmentosa |  |  |
| RYBREVANT (amivantamab) |  |  |  |
| RYBREVANT (amivantamab) | Colorectal Cancer |  |  |
| RYBREVANT (amivantamab) | Colorectal Cancer 2L |  |  |
| RYBREVANT (amivantamab) | Frontline Non Small Cell Lung Cancer in combination with chemotherapy |  |  |
| seltorexant | Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms |  |  |
| SIMPONI (golimumab) | Pediatric Ulcerative Colitis |  |  |
| SIRTURO | Leprosy |  |  |
| SIRTURO | Tuberculosis Long Acting |  |  |
| SPRAVATO (esketamine) | Major Depressive Disorder with Suicidal Ideation Pediatrics |  |  |
| SPRAVATO (esketamine) | Treatment Resistant Depression monotherapy |  |  |
| STELARA (ustekinumab) | Pediatric Crohn's Disease |  |  |
| STELARA (ustekinumab) | Pediatric Ulcerative Colitis |  |  |
| TALVEY (talquetamab) | Relapsed Refractory Multiple Myeloma A-CD38 Naïve |  |  |
| TALVEY (talquetamab) | Relapsed Refractory Multiple Myeloma CD38 exposed |  |  |
| TALVEY + TECVAYLI | Relapsed Refractory Multiple Myeloma |  |  |
| TALVEY + TECVAYLI | Relapsed Refractory Multiple Myeloma CD38 exposed |  |  |
| TALVEY + TECVAYLI | TIE NDMM in combination with DR |  |  |
| TAR-210 (RIS/erdafitinib) | Intravesical Delivery System for Localized Bladder Cancer |  |  |
| TECVAYLI (teclistamab) | Multiple Myeloma 1-3PLs |  |  |
| TECVAYLI (teclistamab) | Relapsed Refractory Multiple Myeloma CD38 exposed |  |  |
| TECVAYLI (teclistamab) | TE NDMM maintenance |  |  |
| TECVAYLI (teclistamab) | TIE NDMM in combination with DR |  |  |
| TREMFYA (guselkumab) | Pediatric Juvenile Psoriatic Arthritis |  |  |
| TREMFYA (guselkumab) | Pediatric Psoriasis |  |  |
| TREMFYA (guselkumab) | Pediatric Ulcerative Colitis |  |  |
| TREMFYA (guselkumab) | Psoriatic Arthritis Structural Damage |  |  |
| TREMFYA (guselkumab) | Ulcerative Colitis Subcutaneous Induction |  |  |
| UPTRAVI (selexipag) | Pediatric Pulmonary Arterial Hypertension |  |  |

## Notes & limitations
- This snapshot reflects public-source extraction; verify critical items in the stored source PDF.
- Phase information can be encoded visually (e.g., color); corroboration is provided via CT.gov where matched.
